TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04536532
Drug: HEC121120 placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study: NCT03879577
Drug: FEC
Normalized name: Fectrim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
Study: NCT03879577
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to all premenopausal patients.
Study: NCT01903200
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01639521
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01639521
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00294567
Drug: Calcium channel blockers (amlodipine, azelnidipine)
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: amlodipine Drug: azelnidipine
Study: NCT01959971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous
Study: NCT00537082
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily for 6 months
Study: NCT00537082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily for 6 months
Study: NCT00773110
Drug: 20% Human albumin solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
Study: NCT00773110
Drug: Gelofusin
Normalized name: Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
Study: NCT03850301
Drug: XBD173
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days treatment
Study: NCT02793778
Drug: CROWN Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
Study: NCT03769168
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
Study: NCT00260390
Drug: Testoviron
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04607785
Drug: Miswak mouthwash group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for seven days for two months
Study: NCT02569905
Drug: flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flurbiprofen 50mg
Study: NCT04026451
Drug: Deep sedation with propofol andfentanyl
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
Study: NCT01902303
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual micro dosing of placebo for 7 days
Study: NCT04682964
Drug: Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
Study: NCT01699685
Drug: QAB149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study: NCT01699685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study: NCT01699685
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study: NCT03189511
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin 40 mg twice daily per mouth for 14 days.
Study: NCT00553306
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002482
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03112187
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
Study: NCT01161121
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
Study: NCT00598975
Drug: NKTR-102 100 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled.
Study: NCT03718403
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline will be given to maintain a peak level between 10-15 mcg/mL
Study: NCT00252889
Drug: Topotecan and pegylated doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
Study: NCT04701983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Study: NCT00983957
Drug: Ortho Tri-Cyclen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, once daily, 78 days
Study: NCT02500342
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study: NCT02500342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT01745302
Drug: TCM
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
Study: NCT01210911
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
Study: NCT02327247
Drug: PLENDIL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended Release Tablets, 10mg
Study: NCT04488419
Drug: ATH-1017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Study: NCT04488419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Study: NCT01432353
Drug: DFRF4539A
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple ascending doses
Study: NCT01971593
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00324194
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 oral dose given 2 times per week.
Study: NCT01696214
Drug: Theophylline 400 mg
Normalized name: theophylline 400 MG
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be assigned to theophylline once a day for 24 weeks
Study: NCT02957123
Drug: Intranasal auto-M2-BFs
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
Study: NCT00449007
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 months
Study: NCT04333654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT03511066
Drug: CT-P27 90 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A treatment drug.
Study: NCT03511066
Drug: CT-P27 45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A treatment drug.
Study: NCT03511066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo.
Study: NCT01089543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
Study: NCT03693508
Drug: Genvoya®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
Study: NCT01898091
Drug: Neem Mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Study: NCT01898091
Drug: Placebo Mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Study: NCT02575183
Drug: Varinecline (Chantix)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
Study: NCT03792867
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
Study: NCT02575183
Drug: Placebo (for Varenicline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
Study: NCT01725308
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth (orally).
Study: NCT01725308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth (orally).
Study: NCT00598975
Drug: NKTR-102 125 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled.
Study: NCT04560114
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary.
Study: NCT03593447
Drug: non-cirrhotic subjects. low TG-2349+ low DAG181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: TG-2349 200 mg + DAG181 100 mg
Study: NCT03593447
Drug: non-cirrhotic subjects. high TG-2349+ high DAG181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: TG-2349 400 mg + DAG181 200 mg
Study: NCT03593447
Drug: cirrhotic subjects. high TG-2349+ high DAG181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group6: TG-2349 400 mg + DAG181 200 mg
Study: NCT02552654
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg
Study: NCT02552654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01812746
Drug: BIND-014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02484729
Drug: AZD9977, oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
Study: NCT02484729
Drug: Placebo, oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02484729
Drug: AZD9977, oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9977, single dose of oral solution in Part B as reference
Study: NCT02218268
Drug: Pre-meal bolus
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
Study: NCT02218268
Drug: No meal bolus
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long Acting insulin as scheduled per usual routine (given once daily)
Study: NCT03724097
Drug: target drug with the score above 0,1
Approvals — FDA: no, EMA: no, PMDA: no
Description: target drug with the score above 0,1
Study: NCT03724097
Drug: target drug with the score equal or below 0,1
Approvals — FDA: no, EMA: no, PMDA: no
Description: target drug with the score equal or below 0,1
Study: NCT03724097
Drug: non-target drug
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-target drug
Study: NCT03724097
Drug: palliative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: palliative care
Study: NCT00689052
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04227522
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
Study: NCT01740427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT02926196
Drug: MSB0010718C
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
Study: NCT02614066
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT03542357
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT00541489
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg, bid
Study: NCT00541489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid
Study: NCT00531817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Study: NCT00531817
Drug: Permitted DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
Study: NCT03624036
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01514175
Drug: IV Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Study: NCT01514175
Drug: IV Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Study: NCT01691313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT01666613
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
Study: NCT01666613
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution to be administered orally Total dose of 950 µg AZD8683
Study: NCT01666613
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
Study: NCT01666613
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
Study: NCT02025036
Drug: Capecitabine(Aibin)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
Study: NCT01390584
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01390584
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: May be given orally, IV push, or by IV infusion
Study: NCT03782103
Drug: ZuraPrep Clear Solution
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT03782103
Drug: ZuraPrep Vehicle
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT00220714
Drug: atypical antipsychotics:oral vs. long-acting route
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04428593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study: NCT00562861
Drug: placebo + mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
Study: NCT02473263
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
Study: NCT02473263
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
Study: NCT02405065
Drug: HM95573
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
Study: NCT02687165
Drug: Milnacipran and D-cycloserine
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran augmented by D-cycloserine
Study: NCT04007874
Drug: Ethinylestradiol/levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
Study: NCT00667589
Drug: bland emollient cream (Udderly smooth® Udder Cream)
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: bland emollient cream applied twice per day to affected areas
Study: NCT00002836
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
Study: NCT00553475
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Study: NCT00484900
Drug: Co-Arinate FDC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03061331
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM 400 mg/IVA 250 mg every 12 hours (q12h)